齐拉西酮与利培酮治疗精神分裂症的临床对照研究

目的探讨齐拉西酮与利培酮治疗精神分裂症的临床疗效与安全性。方法将60例符合《中国精神障碍分类与诊断标准》第三版（CCMD-3）诊断的精神分裂症患者随机分为研究组和对照组各30例,分别予以齐拉西酮与利培酮治疗,疗程8周。分别于治疗前及治疗第8周末采用阳性症状和阴性症状量表（positive symptoms and negative symp-toms scale,PANSS）评定疗效,以治疗中出现的不良反应采用副反应量表（treatment emergent symptom scale,TESS）进行评定。结果治疗8周后,齐拉西酮组的显效率为66.7%,总有效率为86.7%,利培酮组的显效率为70%,总有效率为90%,两组比较,差异无统计学意义（P〉0.05）。两组PANSS评分治疗后均较治疗前明显下降,两组比较,差异有统计学意义（P〈0.05）。齐拉西酮组引起患者锥体外系副反应,体重增加,女性月经改变等方面的几率明显少于利培酮组。结论齐拉西酮对精神分裂症疗效与利培酮相当,不良反应较少,依从性好

The Comparative Investigation between Ziprasidone and Risperidone in the Treatment of Schizophrenia

Objective To explore the clinical efficacy and safety of ziprasidone and risperidone in the treatment of schizophrenia.Methods 60 patients cases met the CCMD-3 diagnosis of schizophrenia were randomly assigned to ziprasidone group（n=30） or risperidone group（n=30）.The efficacy of patients were assessed with the positive symptoms and negative symptoms scale（PANSS）,and the side efficacy was evaluated with treatment emergent symptom scale（TESS）.Results After 8 weeks treatment,the marked improvement rate was 66.7% and effective rate was 86.7% in ziprasidone group,while 70% and 90% in risperidone group,and there were no significant differences between two groups（P〉0.05）.After treatment,the two groups showed significant differences compared with the PANSS.Frequency of extrapyramidal reactions,weight gain,and menstrual changes in women were significantly less in ziprasidone group than in risperidone.Conclusion Ziprasidone was as effective as risperidone for the treatment of schizophrenia and has good compliance,fewer side effects.